Page 2511 - Hematology_ Basic Principles and Practice ( PDFDrive )

2237.e6 Part XII Hemostasis and Thrombosis

with cancer—a prospective study. Med Pediatr Oncol 38:405–410, 262. Tabori U, Beni-Adani L, Dvir R, et al: Risk of venous thromboem-
2002. bolism in pediatric patients with brain tumors. Pediatr Blood Cancer
242. Knöfler R, Siegert E, Lauterbach I, et al: Clinical importance of pro- 43:633–636, 2004.
thrombotic risk factors in pediatric patients with malignancy—impact 263. Deitcher S, Gajjar A, Kun L, et al: Clinically evident venous thrombo-
of central venous lines. Eur J Pediatr 158(Suppl 3):S147, 1999. embolic events in children with brain tumors. J Pediatr 145:848–850,
243. Glaser DW, Medeiros D, Rollins N, et al: Catheter-related thrombosis 2004.
in children with cancer. J Pediatr 138:255–259, 2001. 264. O’Brien SH, Klima J, Termuhlen AM, et al: Venous thromboembolism
244. Wilimas JA, Hudson M, Rao B, et al: Late vascular occlusion of central and adolescent and young adult oncology inpatients in US children’s
lines in pediatric malignancies. Pediatrics 101:E7, 1998. hospitals, 2001 to 2008. J Pediatr 159(1):133–137, 2011.
245. Mitchell LG, PARKAA Group: A prospective cohort study determining 265. Monagle P: Thrombosis in pediatric cardiac patients. Semin Thromb
the prevalence of thrombotic events in children with acute lymphoblastic Hemost 29(6):547–555, 2003.
leukemia and a central venous line who are treated with L-asparaginase: 266. Lynch JK: The hospitalization of childhood stroke in the United States.
results of the Prophylactic Antithrombin Replacement in Kits with Stroke 34:287, 2003.
Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) 267. Freed MD, Keane JF, Rosenthal A: The use of heparinization to
Study. Cancer 97:508–516, 2003. prevent arterial thrombosis after percutaneous cardiac catheterization
246. Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al: Clinical in children. Circulation 50(3):565–569, 1974.
relevance of genetic risk factors for thrombosis in paediatric oncol- 268. Luceri MJ, Tala JA, Weismann CG, et al: Prevalence of post-thrombotic
ogy patients with central venous catheters. Eur J Pediatr 158(Suppl syndrome after cardiac catheterization. Pediatr Blood Cancer 62:1222,
3):S143–S146, 1999. 2015.
247. Massicotte P, Julian JA, Gent M, et al: An open-label randomized 269. Monagle P, Karl TR: Thrombembolic problems after the Fontan opera-
controlled trial of low molecular weight heparin for the prevention of tion. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 5:36–47,
central venous line-related thrombotic complications in children: the 2002.
PROTEKT trial. Thromb Res 109(2–3):101–108, 2003. 270. Seipelt RG, Franke A, Vazquez-Jimenez JF, et al: Thromboembolic
248. Athale U, Siciliano S, Thabane L, et al: Epidemiology and clinical complications after Fontan procedures: comparison of different thera-
risk factors predisposing to thromboembolism in children with cancer. peutic approaches. Ann Thorac Surg 74(2):556–562, 2002.
Pediatr Blood Cancer 51(6):792–797, 2008. 271. Monagle P, Chan AK, Goldenberg NA, et al: Antithrombotic therapy
249. Revel-Vilk S, Yacobovich J, Tamary H, et al: Risk factors for central in neonates and children: antithrombotic therapy and prevention of
venous catheter thrombotic complications in children and adolescents thrombosis, 9th ed: American College of Chest Physicians Evidence-
with cancer. Cancer 116(17):4197–4205, 2010. Based Clinical Practice Guidelines. Chest 141(2 Suppl):e737S–801S,
250. Halton J, Nagel K, Brandão LR, et al: Do children with central venous 2012.
line (CVL) dysfunction have increased risk of symptomatic throm- 272. Monagle P, Cochrane A, Roberts R, et al: A multicenter, randomized
boembolism compared to those without CVL-dysfunction, while on trial comparing heparin/warfarin and acetylsalicylic acid as primary
cancer therapy? BMC Cancer 12:314, 2012. thromboprophylaxis for 2 years after the Fontan procedure in children.
251. Korones D, Buzzard C, Asselin B, et al: Right atrial thrombi in chil- J Am Coll Cardiol 58(6):645–651, 2011.
dren with cancer and indwelling catheters. J Pediatr 128:841–846, 273. Ohuchi H, Yasuda K, Miyazaki A, et al: Prevalence and predictors
1996. of haemostatic complications in 412 Fontan patients: their relation
252. Polen E, Weintraub M, Stoffer C, et al: Post-thrombotic syndrome to anticoagulation and haemodynamics. Eur J Cardiothorac Surg
after central venous catheter removal in childhood cancer survivors: a 47(3):511–519, 2015.
prospective cohort study. Pediatr Blood Cancer 62:285, 2015. 274. Emani S, Trainor B, Zurakowski D, et al: Aspirin unresponsiveness
253. De Cicco M: The prothrombotic state in cancer: pathogenic mecha- predicts thrombosis in high-risk pediatric patients after cardiac surgery.
nisms. Crit Rev Oncol Hematol 50:187–196, 2004. J Thorac Cardiovasc Surg 148(3):810, 2014.
254. Zia AN, Chitlur M: Management of thrombotic complications in acute 275. Bauman ME, Moher C, Bruce AK, et al: Chylothorax in children
lymphoblastic leukemia. Indian J Pediatr 80(10):853–862, 2013. with congenital heart disease: incidence of thrombosis. Thromb Res
255. Lipay NV, Zmitrovich AI, Aleinikova OV: Epidemiology of venous 132(2):e83–e85, 2013.
thromboembolism in children with malignant diseases: a single-center 276. Law YM, Sharma S, Feingold B, et al: Clinically significant thrombosis
study of the Belarusian Center for Pediatric Oncology and Hematology. in pediatric heart transplant recipients during their waiting period.
Thromb Res 128(2):130–134, 2011. Pediatr Cardiol 34(2):334–340, 2013.
256. Caruso V, Iacoviello L, Di Castelnuovo A, et al: Thrombotic compli- 277. Schlegel N: Thromboembolic risks and complications in nephrotic
cations in childhood acute lymphoblastic leukemia: a meta-analysis children. Semin Thromb Hemost 23(3):271–280, 1997.
of 17 prospective studies comprising 1752 pediatric patients. Blood 278. Mehls O, Andrassy K, Koderisch J, et al: Hemostasis and thromboem-
108(7):2216–2222, 2006. bolism in children with nephrotic syndrome: differences from adults.
257. Athale UH, Chan AK: Thrombosis in children with acute lympho- J Pediatr 110(6):862–867, 1987.
blastic leukaemia: pathogenesis of thrombosis in children with acute 279. Egli F: Thromboembolism Beim Nephrotischen Syndrom im Kendesalter,
lymphoblastic leukaemia: effect of the disease and therapy. Thromb Res Basel, 1974, University of Basel.
111:199–212, 2003. 280. Kerlin BA, Blatt NB, Fuh B, et al: Epidemiology and risk factors for
257a. Santoro N, et al: Screening for coagulopathy and identification of thromboembolic complications of childhood nephrotic syndrome: a
children with acute lymphoblastic leukemia at a higher risk of symp- Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr
tomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol 155(1):105, 2009.
Oncol 35(5):348–355, 2013. 281. Tavil B, Kara F, Topaloglu R, et al: Case series of thromboembolic
258. Al-Aridi C, Abboud MR, Saab R, et al: Thrombosis in children complications in childhood nephrotic syndrome: hacettepe experience.
with acute lymphoblastic leukemia treated at a tertiary care center in Clin Exp Nephrol 19:506, 2015.
lebanon: revisiting the role of predictive models. Pediatr Hemat Oncol 282. Hoyer PF, Gonda S, Barthels M, et al: Thromboembolic complications
28(8):676–681, 2011. in children with nephrotic syndrome: risk and incidence. Acta Paediatr
259. Paz-Priel I, Long L, Helman LJ, et al: Thromboembolic events Scand 75(5):804–810, 1986.
in children and young adults with pediatric sarcoma. J Clin Oncol 283. Hogg RJ, Portman RJ, Milliner D, et al: Evaluation and management
25(12):1519–1524, 2007. of proteinuria and nephrotic syndrome in children: recommendations
260. Athale U, Cox S, Siciliano S, et al: Thromboembolism in children with from a pediatric nephrology panel established at the National Kidney
sarcoma. Pediatr Blood Cancer 49:171, 2007. Foundation Conference on Proteinuria Albuminuria, Risk, Assessment,
261. Lee A, Levine M: Venous thromboembolism and cancer: risks and Detection, and Elimination (PARADE). Pediatrics 105(6):1242–1249,
outcomes. Circulation 107(Suppl 1):I17, 2003. 2000.